<DOC>
	<DOCNO>NCT02500914</DOCNO>
	<brief_summary>This Phase 1a/1b study SC-002 patient relapse small cell lung cancer ( SCLC ) large cell neuroendocrine carcinoma ( LCNEC ) . SC-002 antibody-drug conjugate ( ADC ) comprise monoclonal antibody link potent chemotherapy . The purpose study assess safety tolerability SC-002 different dose level , determine high dose SC-002 give patient SCLC LCNEC , evaluate side effect SC-002 , assess anti-cancer activity SC-002 .</brief_summary>
	<brief_title>SC-002 Small Cell Lung Cancer Large Cell Neuroendocrine Carcinoma</brief_title>
	<detailed_description>Part 1A dose escalation study patient small cell lung cancer large cell neuroendocrine carcinoma cytologically confirm , limited extensive SCLC LCNEC relapse refractory limited extensive disease follow 2 prior chemotherapy regimen . Part 1B expansion study patient enrol treated order characterize safety preliminary efficacy patient SCLC LCNEC characterize PK , immunogenicity target expression possible relationship clinical outcome .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<criteria>Histologically cytologically confirm SCLC ( either limit extensive disease ) LCNEC , relapse current treatment refractory treatment Evidence progressive disease follow 2 prior chemotherapy regimens Measurable disease define RECIST ECOG performance status 0 1 Adequate hematological organ function confirm laboratory value Treatment anticancer/investigational drug , therapy â‰¤ 4 week prior first dose SC002 Active central nervous system metastasis Uncontrolled cardiac disease Positive serology hepatitis B hepatitis C know HIV infection Presence condition may increase risk associate study participation interfere interpretation study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>small cell lung cancer</keyword>
	<keyword>large cell neuroendocrine carcinoma</keyword>
</DOC>